NRXPW
NRx Pharmaceuticals, Inc.
Price Chart
Latest Quote
$0.00
Current Price| Open | $0.16 |
| Day High | $0.00 |
| Day Low | $0.00 |
| Volume | 176,260 |
Stock Information
| Total Debt | $934K |
| Cash Equivalents | $6.71M |
| Revenue | $2.29M |
| Net Income | $-24.54M |
| EPS (TTM) | $-6.25 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Sales | $2.29M |
| Income | $-24.54M |
| Book/sh | $-0.41 |
| Employees | 29 |
Financial Ratios
| Quick Ratio | 0.27 |
| Current Ratio | 0.29 |
Returns & Margins
| ROA | -110.22% |
| Gross Margin | 50.46% |
| Operating Margin | -444.57% |
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
| P/B | -0.01 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $0.01 |
| SMA50 | $0.01 |
| RSI | nan |
| Shares Float | 30.45M |
| Volatility | 2.02 |
Performance History
| Week | +0.00% |
| Month | +0.00% |
| YTD | -61.10% |
| 10 Years | -61.10% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-05-28 | $0.01 | 0 |
| 2026-05-27 | $0.01 | 0 |
| 2026-05-26 | $0.01 | 0 |
| 2026-05-22 | $0.01 | 0 |
| 2026-05-21 | $0.01 | 0 |
| 2026-05-20 | $0.01 | 0 |
| 2026-05-19 | $0.01 | 0 |
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone in Phase 2/3 clinical testing for bipolar depression with sub-acute ideation and behavior; NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression; and KETAFREE, a generic preservative-free formulation of ketamine. It also provides precision-based interventional psychiatry services to patients with treatment-resistant depression and PTSD using a combination of neuroplastic drugs, transcranial magnetic stimulation (TMS), digital therapeutics, and hyperbaric therapy; ketamine infusion therapy; stellate ganglion blocks; Spravato administration; psychotherapy; and medication management. The company has a development and license agreement with Glytech LLC. NRx Pharmaceuticals, Inc. was founded in 2015 and is headquartered in Wilmington, Delaware.
đ° Latest News
NRX Pharmaceuticals Inc (NRXP) Q1 2026 Earnings Call Highlights: Strategic Advances Amid ...
GuruFocus.com âĸ 2026-06-17T22:19:52ZNRx Pharmaceuticals (NRXP) Closes Underwritten Public Offering of Common Stock At $3.50 Per Share
Insider Monkey âĸ 2026-06-10T18:22:40Z
Here is why NRx Pharmaceuticals, Inc. (NRXP) is among the Best Rated Penny Stocks to Buy According to Wall Street Analysts
Insider Monkey âĸ 2026-05-24T11:49:17Z
NRx Pharmaceuticals, Inc. (NRXP) Reports Q1 Loss, Lags Revenue Estimates
Zacks âĸ 2026-05-15T21:55:02Z
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
Market Exclusive âĸ 2026-04-06T13:08:33ZNRx Pharmaceuticals (NASDAQ:NRXP) Is In A Good Position To Deliver On Growth Plans
Simply Wall St. âĸ 2026-03-29T13:25:23Z
NRx Pharmaceuticals (NRXP) Looks to Score Double With ANDA and NDA Filings For NRX-101
Insider Monkey âĸ 2026-03-25T18:14:36Z
NRx Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary
Moby âĸ 2026-03-25T12:30:00Z
NRX Pharmaceuticals Inc (NRXP) Q4 2025 Earnings Call Highlights: Strategic Advances and ...
GuruFocus.com âĸ 2026-03-24T19:00:41ZNRx Pharmaceuticals Q4 Earnings Call Highlights
MarketBeat âĸ 2026-03-24T13:10:44Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $432,000 | $0 | - | - |
| Cost Of Revenue | $505,000 | $0 | - | - |
| Total Revenue | $1,225,000 | $0 | $0 | $0 |
| Operating Revenue | $1,225,000 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $671,000 | $230,000 | $120,000 | $0 |
| Total Expenses | $17,449,000 | $18,502,000 | $27,587,000 | $44,335,000 |
| Other Income Expense | $-11,739,000 | $-6,438,000 | $-2,937,000 | $4,332,000 |
| Other Non Operating Income Expenses | $-10,870,000 | $-4,781,000 | $-2,707,000 | $-505,000 |
| Net Non Operating Interest Income Expense | $-659,000 | $-186,000 | $374,000 | $249,000 |
| Interest Expense Non Operating | $671,000 | $230,000 | $120,000 | $0 |
| Operating Expense | $16,944,000 | $18,502,000 | $27,587,000 | $44,335,000 |
| Other Operating Expenses | $36,000 | $-1,202,000 | $250,000 | - |
| General And Administrative Expense | $13,061,000 | $13,500,000 | $14,216,000 | $27,308,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-28,622,000 | $-25,126,000 | $-30,150,000 | $-39,754,000 |
| Net Interest Income | $-659,000 | $-186,000 | $374,000 | $249,000 |
| Interest Income | $12,000 | $44,000 | $494,000 | $249,000 |
| Normalized Income | $-27,788,000 | $-23,469,000 | $-29,920,000 | $-44,591,000 |
| Net Income From Continuing And Discontinued Operation | $-28,622,000 | $-25,126,000 | $-30,150,000 | $-39,754,000 |
| Total Operating Income As Reported | $-16,224,000 | $-18,502,000 | $-27,837,000 | $-44,335,000 |
| Net Income Common Stockholders | $-28,622,000 | $-25,126,000 | $-30,159,000 | $-39,754,000 |
| Net Income | $-28,622,000 | $-25,126,000 | $-30,150,000 | $-39,754,000 |
| Net Income Including Noncontrolling Interests | $-28,622,000 | $-25,126,000 | $-30,150,000 | $-39,754,000 |
| Net Income Continuous Operations | $-28,622,000 | $-25,126,000 | $-30,150,000 | $-39,754,000 |
| Pretax Income | $-28,622,000 | $-25,126,000 | $-30,150,000 | $-39,754,000 |
| Earnings From Equity Interest | $-35,000 | - | - | - |
| Interest Income Non Operating | $12,000 | $44,000 | $494,000 | $249,000 |
| Operating Income | $-16,224,000 | $-18,502,000 | $-27,587,000 | $-44,335,000 |
| Depreciation Amortization Depletion Income Statement | $70,000 | $5,000 | - | - |
| Depreciation And Amortization In Income Statement | $70,000 | $5,000 | - | - |
| Gross Profit | $720,000 | $0 | - | - |
| Special Income Charges | - | - | $-250,000 | $4,582,000 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-26,974,000 | $-23,234,000 | $-29,795,000 | $-44,587,000 |
| Total Unusual Items | $-834,000 | $-1,657,000 | $-230,000 | $4,837,000 |
| Total Unusual Items Excluding Goodwill | $-834,000 | $-1,657,000 | $-230,000 | $4,837,000 |
| Reconciled Depreciation | $143,000 | $5,000 | $5,000 | $4,000 |
| EBITDA (Bullshit earnings) | $-27,808,000 | $-24,891,000 | $-30,025,000 | $-39,750,000 |
| EBIT | $-27,951,000 | $-24,896,000 | $-30,030,000 | $-39,754,000 |
| Diluted NI Availto Com Stockholders | $-28,622,000 | $-25,126,000 | $-30,159,000 | $-39,754,000 |
| Gain On Sale Of Security | $-834,000 | $-1,657,000 | $20,000 | $255,000 |
| Research And Development | $3,777,000 | $6,199,000 | $13,371,000 | $17,027,000 |
| Selling General And Administration | $13,061,000 | $13,500,000 | $14,216,000 | $27,308,000 |
| Other Gand A | $13,061,000 | $13,500,000 | $14,216,000 | $27,308,000 |
| Otherunder Preferred Stock Dividend | - | $0 | $9,000 | $0 |
| Other Special Charges | - | - | $250,000 | - |
| Restructuring And Mergern Acquisition | - | - | $0 | $-4,582,000 |
| Tax Provision | - | - | - | $0 |
Fetched: 2026-05-24
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-18,655,000 | $-23,223,000 | $-11,733,000 | $7,409,000 |
| Total Assets | $12,956,000 | $3,651,000 | $7,315,000 | $25,816,000 |
| Total Non Current Assets | $4,064,000 | $349,000 | $431,000 | $21,000 |
| Other Non Current Assets | $253,000 | $339,000 | $431,000 | $21,000 |
| Goodwill And Other Intangible Assets | $2,718,000 | $0 | - | - |
| Other Intangible Assets | $925,000 | - | - | - |
| Current Assets | $8,892,000 | $3,302,000 | $6,884,000 | $25,795,000 |
| Prepaid Assets | $934,000 | $1,859,000 | $2,283,000 | $5,734,000 |
| Receivables | $161,000 | $0 | $6,000 | $7,000 |
| Accounts Receivable | $161,000 | $0 | - | - |
| Cash Cash Equivalents And Short Term Investments | $7,797,000 | $1,443,000 | $4,595,000 | $20,054,000 |
| Cash And Cash Equivalents | $7,797,000 | $1,443,000 | $4,595,000 | $20,054,000 |
| Other Receivables | - | - | $6,000 | $7,000 |
| Cash Financial | - | - | - | $20,054,000 |
| Debt | ||||
| Total Debt | $631,000 | $6,577,000 | $9,161,000 | $10,525,000 |
| Long Term Debt And Capital Lease Obligation | $315,000 | $5,011,000 | - | $2,822,000 |
| Current Debt And Capital Lease Obligation | $316,000 | $1,566,000 | $9,161,000 | $7,703,000 |
| Net Debt | - | $5,134,000 | $4,566,000 | - |
| Long Term Debt | - | $5,011,000 | - | $2,822,000 |
| Current Debt | - | $1,566,000 | $9,161,000 | $7,703,000 |
| Other Current Borrowings | - | $1,566,000 | $9,161,000 | $7,703,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $28,893,000 | $26,874,000 | $19,048,000 | $18,407,000 |
| Total Non Current Liabilities Net Minority Interest | $315,000 | $5,011,000 | $0 | $2,822,000 |
| Current Liabilities | $28,578,000 | $21,863,000 | $19,048,000 | $15,585,000 |
| Other Current Liabilities | $12,304,000 | $5,639,000 | $17,000 | $37,000 |
| Payables And Accrued Expenses | $9,953,000 | $9,366,000 | $9,035,000 | $7,845,000 |
| Payables | $4,270,000 | $4,130,000 | $4,632,000 | $2,076,000 |
| Accounts Payable | $4,270,000 | $4,130,000 | $4,632,000 | $2,076,000 |
| Current Notes Payable | - | - | - | $0 |
| Equity | ||||
| Common Stock Equity | $-15,937,000 | $-23,223,000 | $-11,736,000 | $7,409,000 |
| Total Equity Gross Minority Interest | $-15,937,000 | $-23,223,000 | $-11,733,000 | $7,409,000 |
| Stockholders Equity | $-15,937,000 | $-23,223,000 | $-11,733,000 | $7,409,000 |
| Retained Earnings | $-306,895,000 | $-278,273,000 | $-253,147,000 | $-222,997,000 |
| Long Term Equity Investment | $397,000 | $0 | - | - |
| Gains Losses Not Affecting Retained Earnings | - | $0 | $-3,000 | $0 |
| Preferred Stock Equity | - | - | $3,000 | - |
| Other Equity Adjustments | - | - | $-3,000 | - |
| Other | ||||
| Ordinary Shares Number | $31,734,333 | $14,591,505 | $8,391,955 | $6,644,298 |
| Share Issued | $31,734,333 | $14,591,505 | $8,391,955 | $6,644,298 |
| Tangible Book Value | $-18,655,000 | $-23,223,000 | $-11,736,000 | $7,409,000 |
| Invested Capital | $-15,937,000 | $-16,646,000 | $-2,575,000 | $17,934,000 |
| Working Capital | $-19,686,000 | $-18,561,000 | $-12,164,000 | $10,210,000 |
| Capital Lease Obligations | $631,000 | $0 | - | - |
| Total Capitalization | $-15,937,000 | $-18,212,000 | $-11,733,000 | $10,231,000 |
| Additional Paid In Capital | $290,926,000 | $255,035,000 | $241,406,000 | $230,339,000 |
| Capital Stock | $32,000 | $15,000 | $11,000 | $67,000 |
| Common Stock | $32,000 | $15,000 | $8,000 | $67,000 |
| Preferred Stock | $0 | $0 | $3,000 | $0 |
| Long Term Capital Lease Obligation | $315,000 | $0 | - | - |
| Current Capital Lease Obligation | $316,000 | $0 | - | - |
| Pensionand Other Post Retirement Benefit Plans Current | $496,000 | $577,000 | $835,000 | - |
| Current Provisions | $5,509,000 | $4,715,000 | - | - |
| Current Accrued Expenses | $5,683,000 | $5,236,000 | $4,403,000 | $5,769,000 |
| Investments And Advances | $397,000 | $0 | - | - |
| Goodwill | $1,793,000 | $0 | - | - |
| Net PPE | $696,000 | $10,000 | - | - |
| Gross PPE | $696,000 | $10,000 | - | - |
| Other Properties | $696,000 | $10,000 | - | - |
Fetched: 2026-05-24
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-14,112,000 | $-10,637,000 | $-21,660,000 | $-39,765,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-14,112,000 | $-10,637,000 | $-21,657,000 | $-39,755,000 |
| Cash Flow From Continuing Operating Activities | $-14,112,000 | $-10,637,000 | $-21,657,000 | $-39,755,000 |
| Operating Gains Losses | $7,070,000 | $2,935,000 | $-20,000 | $-255,000 |
| Investing Activities | ||||
| Investing Cash Flow | $-2,810,000 | $0 | $-3,000 | $-10,000 |
| Cash Flow From Continuing Investing Activities | $-2,810,000 | $0 | $-3,000 | $-10,000 |
| Capital Expenditure | - | - | $-3,000 | $-10,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $15,860,000 | $5,911,000 | $9,293,000 | $22,702,000 |
| Financing Cash Flow | $23,276,000 | $7,485,000 | $6,201,000 | $32,214,000 |
| Cash Flow From Continuing Financing Activities | $23,276,000 | $7,485,000 | $6,201,000 | $32,214,000 |
| Net Other Financing Charges | $-350,000 | $-896,000 | - | - |
| Net Common Stock Issuance | $15,860,000 | $5,911,000 | $8,122,000 | $22,702,000 |
| Common Stock Issuance | $15,860,000 | $5,911,000 | $8,122,000 | $22,702,000 |
| Net Preferred Stock Issuance | - | $0 | $1,171,000 | $0 |
| Preferred Stock Issuance | - | $0 | $1,171,000 | $0 |
| Other | ||||
| Repayment Of Debt | $-548,000 | $-8,575,000 | $-4,035,000 | $-518,000 |
| Issuance Of Debt | $5,227,000 | $7,079,000 | $943,000 | $10,020,000 |
| Interest Paid Supplemental Data | $0 | $374,000 | $885,000 | $0 |
| Income Tax Paid Supplemental Data | $0 | $0 | $0 | $0 |
| End Cash Position | $7,797,000 | $1,443,000 | $4,595,000 | $20,054,000 |
| Beginning Cash Position | $1,443,000 | $4,595,000 | $20,054,000 | $27,605,000 |
| Changes In Cash | $6,354,000 | $-3,152,000 | $-15,459,000 | $-7,551,000 |
| Proceeds From Stock Option Exercised | $3,087,000 | $3,966,000 | $0 | $10,000 |
| Net Issuance Payments Of Debt | $4,679,000 | $-1,496,000 | $-3,092,000 | $9,502,000 |
| Net Long Term Debt Issuance | $4,679,000 | $-1,496,000 | $-3,092,000 | $9,502,000 |
| Long Term Debt Payments | $-548,000 | $-8,575,000 | $-4,035,000 | $-518,000 |
| Long Term Debt Issuance | $5,227,000 | $7,079,000 | $943,000 | $10,020,000 |
| Net Investment Purchase And Sale | $-432,000 | $0 | - | - |
| Purchase Of Investment | $-432,000 | $0 | - | - |
| Net Business Purchase And Sale | $-2,378,000 | $0 | - | - |
| Purchase Of Business | $-2,378,000 | $0 | - | - |
| Change In Working Capital | $1,409,000 | $5,291,000 | $5,164,000 | $699,000 |
| Change In Other Current Liabilities | $-118,000 | $0 | - | - |
| Change In Payables And Accrued Expense | $614,000 | $4,788,000 | $2,124,000 | $1,331,000 |
| Change In Accrued Expense | $501,000 | $10,005,000 | $-531,000 | $2,942,000 |
| Change In Payable | $113,000 | $-5,217,000 | $2,655,000 | $-1,611,000 |
| Change In Account Payable | $113,000 | $-5,217,000 | $2,655,000 | $-1,611,000 |
| Change In Prepaid Assets | $865,000 | $503,000 | $3,040,000 | $-632,000 |
| Change In Receivables | $48,000 | $0 | - | $0 |
| Changes In Account Receivables | $48,000 | $0 | - | $0 |
| Other Non Cash Items | $5,620,000 | $5,772,000 | $2,957,000 | $-4,077,000 |
| Stock Based Compensation | $228,000 | $486,000 | $387,000 | $3,628,000 |
| Provisionand Write Offof Assets | $40,000 | $0 | - | - |
| Depreciation Amortization Depletion | $143,000 | $5,000 | $5,000 | $4,000 |
| Depreciation And Amortization | $143,000 | $5,000 | $5,000 | $4,000 |
| Depreciation | $143,000 | $5,000 | $5,000 | $4,000 |
| Earnings Losses From Equity Investments | $35,000 | $0 | - | - |
| Gain Loss On Investment Securities | $-443,000 | $1,657,000 | $-20,000 | $-255,000 |
| Net Income From Continuing Operations | $-28,622,000 | $-25,126,000 | $-30,150,000 | $-39,754,000 |
| Net PPE Purchase And Sale | - | $0 | $-3,000 | $-10,000 |
| Purchase Of PPE | - | $0 | $-3,000 | $-10,000 |
| Net Short Term Debt Issuance | - | - | - | $-518,000 |
| Short Term Debt Payments | - | - | - | $-518,000 |
Fetched: 2026-05-24